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CASE REPORT
Transcutaneous bilirubin monitoring 
predicts unexplained late-onset hemolysis in a 
very low birthweight infant
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and Ichiro Morioka1*
Abstract 
Background: In term infants, transcutaneous bilirubin (TcB) monitoring can be used to predict hemolytic hyperbili‑
rubinemia. However, it is not clear whether the technique can also be used to predict unexplained late‑onset hemoly‑
sis in very low birthweight (VLBW) infants.
Case presentation: The case was an infant with a birthweight of 1154 g who developed unexplained late‑onset 
hemolysis at 8 days of age. The hyperbilirubinemia rapidly worsened, and therefore both phototherapy and exchange 
transfusion were performed. TcB levels were measured using the JM‑105 jaundice meter and found to have increased 
by >3 mg/dL since before the onset, demonstrating for the first time that the device clearly detects changes in hemo‑
lytic rate.
Conclusions: Although TcB levels did not correspond directly with total serum bilirubin levels in VLBW infants, the 
two values exhibited parallel changes in this case. Therefore, serial TcB monitoring may be useful in the early predic‑
tion of unexplained late‑onset hemolysis in VLBW infants.
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Background
Several cases have been reported of hemolytic episodes 
occurring unexpectedly in newborn infants, especially 
very low birthweight (VLBW) infants, who were within 
2–3  weeks old and had a stable cardiovascular status 
[1–4]. This condition is known as late-onset hemolysis, 
and it can develop severe hemolytic hyperbilirubinemia. 
Despite this, its cause is unknown and its onset is difficult 
to predict; the resulting delayed diagnosis leads to a risk 
of kernicterus.
Daily blood sampling to measure total serum bilirubin 
(TSB) may allow early prediction of late-onset hemoly-
sis; in practice however, this is not a suitable option 
for VLBW infants. Herein, we report the first case of a 
VLBW infant with unexplained late-onset hemolysis that 
was predicted using the JM-105 jaundice meter (Konica 
Minolta, Inc., Tokyo, Japan), which allows serial monitor-
ing of transcutaneous bilirubin (TcB) on the basis of yel-
lowness below the skin.
Case presentation
A Japanese girl infant weighing 1154  g was born at 
29 weeks and 6 days of gestational age; her mother had 
received a tocolytic agent and betamethasone due to a 
risk of premature delivery. However, this treatment had 
failed to inhibit uterine contractions, and the girl infant 
was delivered by emergency caesarean section. The girl’s 
Apgar scores were four and six at one and 5  min after 
birth, respectively. The newborn was diagnosed with res-
piratory distress syndrome, so her trachea was intubated 
and an artificial pulmonary surfactant was administered. 
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When the girl was 1 day old, she was extubated; her res-
piratory condition was stable at this time and she was 
further treated using nasal directional positive airway 
pressure (DPAP), as well as a xanthine derivative. Her 
arterial duct closed spontaneously at around this time. 
When she was 2 days old, elevated TSB levels were found 
(9.6 mg/dL), and she was immediately treated using con-
ventional phototherapy, which continued until she was 
5 days old. From the time she was 2 days old, the girl was 
tube-fed; her clinical course was favorable until the event 
described below.
When the girl was 7 days old, her percutaneous oxygen 
saturation (SpO2) decreased to around 90  %, and resid-
ual milk formed; furthermore, blood methemoglobin 
was elevated at 2.4 %. A day later, when she was 8 days 
old, TcB levels in the back were found to be elevated to 
10 mg/dL, and a blood test revealed that both TSB and 
unbound bilirubin (UB) were elevated (to 10.8  mg/dL 
and 0.42  µg/dL, respectively). For these reasons, con-
ventional phototherapy was resumed (phototherapy or 
exchange transfusion is initiated when TSB or UB meas-
ured by FDA-approved UB analyzer [Arrows, Osaka, 
Japan] reached the following cut-offs in a Japanese guide-
line: TSB 12  mg/dL or UB 0.3  µg/dL for phototherapy 
and TSB 18 mg/dL or UB 0.8 µg/dL for exchange trans-
fusion) [5]. When the girl was 9  days old, cyanosis was 
noted, and the SpO2 had decreased to 83 % (nasal DPAP 
parameters: positive end expiratory pressure = 5 cmH2O, 
fraction of inspired oxygen = 0.4). Nonetheless, she was 
doing well, with stable vital signs; her heart rate was 
140 beats/min, and her blood pressure was 65/39 mmHg. 
Subsequently, anemia became markedly worse (hemo-
globin levels = 7.8 g/dL), and blood carboxyhemoglobin 
(COHb) increased to 5 %. Although conventional photo-
therapy was administered, hyperbilirubinemia also wors-
ened (TSB  =  18.4  mg/dL, UB  =  1.48  µg/dL). Because 
of this rapid deterioration in terms of both anemia and 
hyperbilirubinemia, treatment was promptly switched 
to intensive phototherapy, and an exchange transfusion 
was performed. Thereafter, SpO2 immediately increased 
to 100  %, and cyanosis subsided. However, as the TSB 
and UB levels remained at 15.9  mg/dL and 1.15  µg/dL, 
respectively, a second exchange transfusion was per-
formed. When she was 11 days old, as the TSB and UB 
levels had decreased, treatment was switched back to 
conventional phototherapy; this therapy was completed 
when the patient was 13 days old; at that time, the TSB 
and UB had decreased to 5.2  mg/dL and 0.14  µg/dL, 
respectively. No hemolytic episodes occurred thereaf-
ter (TcB =  3.8–8.5  mg/dL, TSB =  4.9–7.5  mg/dL). The 
results of both magnetic resonance imaging and the audi-
tory brain stem response test were normal at the time of 
discharge (38 weeks of corrected gestational age). At the 
corrected age of 18 months, the girl could walk without 
assistance and speak some words; she showed no symp-
toms of kernicterus.
As for the cause of hemolytic jaundice, neither blood 
group incompatibility (mother and child blood groups: 
type O and Rhesus D positive, respectively) nor irregular 
antibodies (anti-C, c, D, E, e, Dia, Dib, Fya, Fyb, Jka, Jkb, S, 
s, M, N, P1, Lea, and Leb antibodies) were detected. Glu-
cose-6-phosphate dehydrogenase deficiency is extremely 
rare in the Japanese population [6, 7]. Although most 
hemolytic cases due to glucose-6-phosphate dehydro-
genase deficiency in Japan are boys from a mother with 
non-Japanese ethnicity [6, 7], this present case is a girl 
and her parents were Japanese without the history of 
hemolysis. No hemolytic relapses occurred thereafter in 
this case. A peripheral blood picture taken when the girl 
was 9 days old confirmed schistocytes and Heinz bodies 
(Fig.  1). Considering her clinical course, the infant was 
diagnosed with unexplained late-onset hemolysis.
Transition of TcB
Figure  2 shows the changes in TSB and TcB levels over 
time, the latter of which was measured using the JM-105 
jaundice meter. TcB levels varied in parallel with TSB 
levels. The linear regression analysis between TSB and 
forehead TcB levels, or back or chest TcB levels in this 
present case showed the following results: the regres-
sion equation and coefficient of determination were 
y  =  0.52x  +  0.84 and 0.64 for forehead TcB levels or 
y = 0.69x + 0.37 and 0.68 for back or chest TcB levels.
When the girl was 8 days old, the TcB level was found 
to have increased by >3 mg/dL over that found when the 
girl was 7  days old. Specifically, TcB levels in her back 
rose from 7.1  mg/dL at 7  days of age to 10.8  mg/dL at 
8  days of age; those in the forehead rose from 4.0  mg/
dL at 7 days of age to 7.5 mg/dL at 8 days of age. Further 
evaluation indicated that this was due to an acute hemo-
lytic episode.
Discussion
To our knowledge, this is the first report describing the 
prediction of unexplained late-onset hemolysis using 
TcB monitoring in a VLBW infant. The following char-
acteristics are seen in unexplained late-onset hemolysis: 
(1) the infant is born preterm, especially with a VLBW; 
(2) despite a stable general condition, hemolytic hyper-
bilirubinemia occurs suddenly 2–3  weeks after birth; 
(3) SpO2 decreases as a result of methemoglobinemia, 
and this is followed by elevation of blood COHb; (4) 
the peripheral blood picture shows Heinz bodies; (5) 
the hemolytic attack is transient and does not relapse; 
and (6) the condition may develop into severe hyper-
bilirubinemia, which requires exchange transfusion in 
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addition to phototherapy [3, 4]. The present case showed 
all these characteristics, allowing a diagnosis of unex-
plained late-onset hemolysis. The etiology of the condi-
tion remains uncertain. One possible causative factor 
in this disease is oxidative stress, perhaps caused by a 
combination of the immature antioxidant capacity of the 
erythrocyte and exposure to highly concentrated oxy-
gen and drugs or toxic agents [3, 8]. Although neonatal 
Heinz body hemolytic anemia can be induced by expo-
sures of vitamin C [9], phenolic disinfectant [10], tolui-
dine blue [11], or methylene blue [12], the present case 
did not expose to these agents. Intravenous vitamin K 
(including sodium hydroxide, lecithin, sorbitol, taurine 
and glycerin) and xanthine derivative (including ethyl-
enediamine), and oral Daikenchuto were taken before 
appearing hemolysis. There was no exposure to cleansers 
on her skin.
As this disease causes severe hyperbilirubinemia, the 
infant is at risk of developing kernicterus. Therefore, it 
is important that hemolytic hyperbilirubinemia is pre-
dicted early and that treatment is initiated likewise. An 
antecedent decrease in SpO2, as well as methemoglobine-
mia, can be considered indicators of the disease. How-
ever, as these phenomena are non-specific, it is difficult 
to predict only hemolysis on their basis alone. Instead, 
measuring TSB daily may allow more specific predic-
tion. Unfortunately, this is an ethically unsuitable option 
in routine clinical practice, because such measurement 
requires frequent blood sampling, thereby increasing 
stress on the infant, as well as accelerating the deteriora-
tion of anemia. Thus, the non-invasive measurement of 
TcB may be a useful tool for predicting this disease.
In full-term and late-preterm infants, TcB measure-
ments are used as a non-invasive tool for predicting 
hemolytic hyperbilirubinemia such as that caused by 
blood group incompatibility as well as hyperbilirubine-
mia from other causes [13–15]. On the other hand, it 
remains unclear whether TcB measurement can be used 
to predict unexplained late-onset hemolysis in VLBW 
infants. In the present case, the TcB level increased by 
>3 mg/dL from 7 days of age to eight, and these changes 
in TcB levels were clearly confirmed. Thus, the infant 
Fig. 1 Peripheral blood pictures. Schistocytes (indicated by arrowheads) and Heinz bodies in the erythrocytes (indicated by arrows) can be seen 
during the development of hemolytic hyperbilirubinemia
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was immediately treated using phototherapy, and subse-
quently using exchange transfusion.
In this present case, a diagnosis of hemolysis was made 
based on a drop in hemoglobin level, detection of Heinz 
bodies in the erythrocytes, and elevated COHb. Meas-
urements of end-tidal breath carbon monoxide corrected 
for ambient carbon monoxide (ETCOc) are used as an 
index of hemolysis [16]. If serial ETCOc measurements 
can be applied to preterm or VLBW infants, ETCOc may 
be a useful tool for early detection of unexplained late-
onset hemolysis.
Conclusion
Serial TcB monitoring may be a useful tool for predict-
ing hemolysis early, not only in term, but also in preterm 
VLBW infants.
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